03:44 PM EST - ProMetic Life Sciences Inc. : announced today that it has successfully completed the required GLP toxicology studies performed by a certified contract research organization confirming that Prometic's lead drug candidate, PBI-4050, is safe to advance into clinical trial stages. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.03 at $0.75.
